Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Simon Boulton and colleagues have found that the 3′–5′ superfamily 2 helicase HELQ is important to prevent germ cell attrition and tumour development in mice.
Leandro Cerchietti, Ari Melnick and colleagues present evidence that DNA methyltransferase inhibitors (DNMTIs) might be one route through which to improve the outcome for patients with diffuse large B cell lymphoma who have a high risk of relapse.
Two recent papers have uncovered important roles for the receptor tyrosine kinase (RTK) AXL in both resistance to inhibitors of the ERBB family of RTKs and inflammation-induced tumorigenesis.
Anaplastic lymphoma kinase (ALK) is commonly altered — through mutation, overexpression or translocation — in many types of cancer, but the role of ALK signalling in mammalian cells and tumours remains enigmatic. What can we learn from model systems? And what progress has been made in targeting this receptor tyrosine kinase?
Krüppel-like factor (KLF) transcriptional regulators have diverse functions in many cancer-relevant processes. This Review discusses the context-dependent roles for KLFs in different cancers and identifies key questions for the field.
This Review discusses mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and molecularly targeted therapies, which share many features. It is hoped that an improved understanding of the molecular basis of resistance will lead to rational drug combinations and predictive biomarkers.
What can we learn about cancer stem cells and tumour tissue hierarchy from what we know about stem cells? Read this Opinion article to find out how our knowledge of normal stem cells applies to cancer stem cells in solid tumours.
Myeloid-derived suppressor cells (MDSCs) remain steeped in mystery and controversy — how do we identify them? How are they recruited to the tumour microenvironment? How do they suppress antitumour immunity? This Timeline article discusses the discovery of MDSCs and what we know now — and need to know in the future — about the role of MDSCs in cancer biology.
